肝细胞-话题@MedSci

#肝细胞#

513篇内容 | 2116人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1863669, encodeId=788d186366934, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效, objectType=article, longId=726452, objectId=a4efe2645295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4efe2645295, replyNumber=0, likeNumber=102, createdTime=2023-01-06, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4efe2645295, moduleTitle=BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4efe2645295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863645, encodeId=331c186364526, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, objectType=article, longId=294335, objectId=1c8d29433575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8d29433575, replyNumber=0, likeNumber=83, createdTime=2022-01-31, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8d29433575, moduleTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8d29433575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863642, encodeId=70581863642f3, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=European Radiology：混合性肝细胞癌-胆管癌的这些MRI表现提示了预后！, objectType=article, longId=294082, objectId=5b4c294082d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4c294082d9, replyNumber=0, likeNumber=78, createdTime=2022-10-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4c294082d9, moduleTitle=European Radiology：混合性肝细胞癌-胆管癌的这些MRI表现提示了预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4c294082d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863652, encodeId=710618636521b, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=CGH: 肝酶水平升高会增加非酒精性脂肪肝患者的肝硬化和肝细胞癌的发生风险, objectType=article, longId=299168, objectId=818029916816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818029916816, replyNumber=0, likeNumber=115, createdTime=2022-04-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818029916816, moduleTitle=CGH: 肝酶水平升高会增加非酒精性脂肪肝患者的肝硬化和肝细胞癌的发生风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818029916816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863636, encodeId=a4571863636c6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, objectType=article, longId=292266, objectId=82df292266f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82df292266f0, replyNumber=0, likeNumber=49, createdTime=2022-09-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82df292266f0, moduleTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82df292266f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863637, encodeId=aff5186363ee7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, objectType=article, longId=292954, objectId=a2d3292954c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d3292954c0, replyNumber=0, likeNumber=66, createdTime=2022-07-15, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d3292954c0, moduleTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d3292954c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863650, encodeId=4aaf1863650ed, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, objectType=article, longId=295266, objectId=a52729526605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52729526605, replyNumber=0, likeNumber=68, createdTime=2022-05-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52729526605, moduleTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52729526605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863663, encodeId=05841863663e3, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, objectType=article, longId=723407, objectId=bf1be2340744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1be2340744, replyNumber=0, likeNumber=93, createdTime=2022-12-12, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1be2340744, moduleTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1be2340744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863659, encodeId=bc4f1863659fa, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效, objectType=article, longId=300542, objectId=048f300542db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048f300542db, replyNumber=0, likeNumber=60, createdTime=2022-10-27, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048f300542db, moduleTitle=Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=048f300542db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863682, encodeId=c2361863682f1, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=European Radiology：使用MRI评价钇-90放射栓塞治疗对肝细胞癌的反应, objectType=article, longId=736492, objectId=da81e36492f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da81e36492f6, replyNumber=0, likeNumber=110, createdTime=2022-09-20, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da81e36492f6, moduleTitle=European Radiology：使用MRI评价钇-90放射栓塞治疗对肝细胞癌的反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da81e36492f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863671, encodeId=b08e18636e129, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响, objectType=article, longId=728103, objectId=4b08e2810361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b08e2810361, replyNumber=0, likeNumber=87, createdTime=2022-06-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b08e2810361, moduleTitle=CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b08e2810361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863657, encodeId=1e2b186365efb, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关, objectType=article, longId=299322, objectId=7c1e299322c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c1e299322c1, replyNumber=0, likeNumber=56, createdTime=2022-10-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c1e299322c1, moduleTitle=Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c1e299322c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863644, encodeId=4fa918636440a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR), objectType=article, longId=294116, objectId=bee2294116f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee2294116f4, replyNumber=0, likeNumber=94, createdTime=2022-04-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee2294116f4, moduleTitle=Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee2294116f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863626, encodeId=c6f018636269e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=47, createdTime=2021-12-15, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863679, encodeId=0c0e18636e9c7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=AP&T: 接种乙肝疫苗可显着降低乙肝病毒感染率和肝细胞癌发病率, objectType=article, longId=735609, objectId=cceae3560960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceae3560960, replyNumber=0, likeNumber=87, createdTime=2022-09-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceae3560960, moduleTitle=AP&T: 接种乙肝疫苗可显着降低乙肝病毒感染率和肝细胞癌发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cceae3560960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863654, encodeId=d30c1863654f3, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Hepatology：肝细胞癌根治性肝切除术后复发的动态风险预测, objectType=article, longId=299224, objectId=f89e299224e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f89e299224e6, replyNumber=0, likeNumber=73, createdTime=2022-11-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f89e299224e6, moduleTitle=Hepatology：肝细胞癌根治性肝切除术后复发的动态风险预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89e299224e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863625, encodeId=4a76186362593, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, objectType=article, longId=220296, objectId=ddf8220296a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddf8220296a1, replyNumber=0, likeNumber=81, createdTime=2022-03-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddf8220296a1, moduleTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddf8220296a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863646, encodeId=381f1863646d4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, objectType=article, longId=294717, objectId=7d23294e17f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d23294e17f3, replyNumber=0, likeNumber=60, createdTime=2022-07-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d23294e17f3, moduleTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d23294e17f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863627, encodeId=a34b186362e97, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响, objectType=article, longId=221166, objectId=25712211662e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25712211662e, replyNumber=0, likeNumber=55, createdTime=2022-03-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25712211662e, moduleTitle=AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25712211662e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863673, encodeId=f39918636e37d, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=2022 ASCO：通过个性化和肿瘤知情的ctDNA检测监测肝细胞癌患者肝脏移植后疾病复发的可行性, objectType=article, longId=728361, objectId=4a1be2836132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a1be2836132, replyNumber=0, likeNumber=73, createdTime=2022-09-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a1be2836132, moduleTitle=2022 ASCO：通过个性化和肿瘤知情的ctDNA检测监测肝细胞癌患者肝脏移植后疾病复发的可行性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a1be2836132)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝细胞

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效

2023-01-06

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素

2022-01-31

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

European Radiology：混合性肝细胞癌-胆管癌的这些MRI表现提示了预后！

2022-10-17

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

CGH: 肝酶水平升高会增加非酒精性脂肪肝患者的肝硬化和肝细胞癌的发生风险

2022-04-17

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150

2022-09-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性

2022-07-15

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险

2022-05-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效

2022-12-12

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：仑伐替尼联合或不联合药物洗脱微球经动脉化疗栓塞治疗不可切除晚期肝细胞癌的疗效

2022-10-27

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

European Radiology：使用MRI评价钇-90放射栓塞治疗对肝细胞癌的反应

2022-09-20

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响

2022-06-24

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：AFP早期应答与仑伐替尼治疗HBV相关肝细胞癌生存相关

2022-10-05

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR)

2022-04-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2021-12-15

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

AP&T: 接种乙肝疫苗可显着降低乙肝病毒感染率和肝细胞癌发病率

2022-09-05

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Hepatology：肝细胞癌根治性肝切除术后复发的动态风险预测

2022-11-09

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估

2022-03-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效

2022-07-08

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

AJG：酒精性肝硬化患者戒酒对肝细胞癌风险的影响

2022-03-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

2022 ASCO：通过个性化和肿瘤知情的ctDNA检测监测肝细胞癌患者肝脏移植后疾病复发的可行性

2022-09-08

科室
- - 订阅+
  - 更多科室
工具
服务